Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · IEX Real-Time Price · USD
37.65
-0.27 (-0.71%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Janux Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Net Income
-58.29-63.06-32.67-6.78-4
Depreciation & Amortization
1.960.840.110.010.01
Share-Based Compensation
20.0117.26.910.070.01
Other Operating Activities
-14.242.098.672.330.16
Operating Cash Flow
-50.58-42.92-16.98-4.37-3.83
Capital Expenditures
-1.85-6.45-1.4800
Change in Investments
-39.3464.71-339.4800
Investing Cash Flow
-41.1958.27-340.9600
Share Issuance / Repurchase
59.550.5205.980.070
Debt Issued / Paid
0002.54
Other Financing Activities
--180.558.95-
Financing Cash Flow
59.550.5386.5211.524
Net Cash Flow
-32.2215.8428.597.160.17
Free Cash Flow
-52.43-49.37-18.46-4.37-3.83
Free Cash Flow Margin
-648.58%-573.24%-507.51%--
Free Cash Flow Per Share
-1.19-1.19-0.78-4.77-5.72
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).